Met Life Investment Management, LLC Cel Sci Corp Transaction History

Met Life Investment Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$3.93 - $7.7 $56,961 - $111,603	-14,494 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$7.1 - $12.82 $102,907 - $185,813	14,494 New	14,494 $102,000
Q3 2021 Jun 21, 2023	BUY	$7.64 - $12.49 $110,734 - $181,030	14,494 New	14,494 $159,000
Q2 2021 Jun 21, 2023	BUY	$8.68 - $27.49 $125,807 - $398,440	14,494 New	14,494 $125,000
Q1 2021 May 17, 2024	BUY	$12.0 - $27.64 $173,928 - $400,614	14,494 New	14,494 $220,000
Q1 2021 Jun 26, 2023	BUY	$12.0 - $27.64 $173,928 - $400,614	14,494 New	14,494 $220 Million
Q1 2021 Mar 22, 2023	SELL	$12.0 - $27.64 $1,164 - $2,681	-97 Reduced 0.66%	14,494 $220,000
Q1 2021 May 14, 2021	SELL	$12.0 - $27.64 $1,164 - $2,681	-97 Reduced 0.66%	14,494 $220,000
Q4 2020 Jun 22, 2023	BUY	$11.05 - $16.62 $161,230 - $242,502	14,591 New	14,591 $170,000
Q3 2020 Jun 26, 2023	BUY	$11.69 - $14.54 $170,568 - $212,153	14,591 New	14,591 $186,000
Q2 2020 May 24, 2024	BUY	$9.75 - $17.6 $142,262 - $256,801	14,591 New	14,591 $218 Million
Q2 2020 Jun 26, 2023	BUY	$9.75 - $17.6 $142,262 - $256,801	14,591 New	14,591 $217,000
Q1 2020 Jul 12, 2023	BUY	$7.54 - $17.05 $110,016 - $248,776	14,591 New	14,591 $168,000
Q4 2019 Jul 12, 2023	BUY	$6.71 - $9.55 $97,905 - $139,344	14,591 New	14,591 $133,000
Q3 2019 Jul 12, 2023	BUY	$6.0 - $9.6 $87,546 - $140,073	14,591 New	14,591 $130,000
Q3 2019 Mar 22, 2023	BUY	$6.0 - $9.6 $87,546 - $140,073	14,591 New	14,591 $130,000
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $87,546 - $140,073	14,591 New	14,591 $130,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $24.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.